Use of Chemotherapeutic and Biologic Agents in Metastatic Breast Cancer Breast Cancer Update Medical Oncology Educational Forum May 21, 2005 Kathy D Miller.

Slides:



Advertisements
Similar presentations
Take home message Breast Cancer Bevacizumab in MBC Sabino De Placido 1.
Advertisements

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.
Integration of Taxanes in the Management of Breast Cancer
Oncologic Drugs Advisory Committee
Metastatic HER2-Positive Breast Cancer: Treatment Selection and Sequencing in the First Line and Beyond Moderator: Joseph Gligorov, MD, PhD Head, Cancer.
SABCS 2012 Guy Jerusalem, MD, PhD. SABCS 2012: Clinical studies in HER2 negative disease Hunderds of oral and poster presentations to be covered (endocrine.
William J. Gradishar MD, FACP Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center For Women's Cancer Care Robert H. Lurie Comprehensive.
Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.
Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)
Drug Treatment of Metastatic Breast Cancer
AVADO PFS Analysis (ITT Population) All P values vs. placebo Adapted from Miles et al. ASCO 2008, abstract LBA 1011.
Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.
A Phase III, Randomized, Double-Blind, Placebo-Controlled Registration Trial to Evaluate the Efficacy and Safety of Placebo + Trastuzumab + Docetaxel vs.
Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single agent (s/a) BEV as maintenance therapy in.
NCCTG N9831 May 2005 Update Perez EA, Suman VJ, Davidson N, Martino S, Kaufman P, on Behalf of NCCTG, ECOG, SWOG, CALGB.
Bevacizumab: Antiangiogenic therapy for breast cancer: where do we stand? Fortunato Ciardiello Division of Medical Oncology, Department of Clinical and.
Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.
Van Cutsem E et al. ASCO 2009; Abstract LBA4509. (Oral Presentation)
Thymidine phosphorylase (TP) upregulation Dose- and time-dependent upregulation of TP in human colon cancer xenografts PaclitaxelDocetaxel.
Il punto di vista del clinico Fabio Puglisi, MD PhD Ruolo della terapia antiangiogenica nel carcinoma mammario.
RIBBON-1: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy with or without Bevacizumab for First-Line Treatment of HER2-Negative.
A Meta-Analysis of Overall Survival Data from Three Randomized Trials of Bevacizumab (BV) and First-Line Chemotherapy as Treatment for Patients with Metastatic.
Anti-angiogenic therapy: a new approach to the treatment of metastatic breast cancer Kathy Miller Indiana University School of Medicine, USA.
Trials of Adjuvant Trastuzumab in HER2+ Early-Stage Breast Cancer Trial Study Regimen No. of Patients Disease-Free Survival (%) Hazard Ratio P-Value Overall.
A Meta-Analysis of Overall Survival Data from Three Trials of Bevacizumab and First-Line Chemotherapy as Treatment for Patients with Metastatic Breast.
Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer.
Herceptin ® : leading the way in metastatic breast cancer care Steffen Kahlert.
Assistant Professor of Medicine Dana-Farber Cancer Institute
The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.
Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma Sternberg CN et al. ASCO 2009; Abstract (Oral Presentation)
1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.
Randomized Phase III Trial Comparing FOLFIRINOX (F: 5FU/Leucovorin [LV], Irinotecan [I], and Oxaliplatin [O]) versus Gemcitabine (G) as First-Line Treatment.
BASED ON PROTOCOL VERSION 1 SEPTEMBER 2012 A new study evaluating an investigational drug to treat patients with HER2-positive metastatic gastroesophageal.
E2100 A Randomized Phase III Trial of Paclitaxel versus Paclitaxel plus Bevacizumab as First- Line Therapy for Locally Recurrent or Metastatic Breast Cancer.
Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized.
Pritchard KI et al. Proc SABCS 2010;Abstract P
A Comparison of Fulvestrant 500 mg with Anastrozole as First-line Treatment for Advanced Breast Cancer: Follow-up Analysis from the FIRST Study Robertson.
AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.
OCEANS: A Randomized, Double- Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-
Kang Y et al. Proc ASCO 2010;Abstract LBA4007.
Time to Secondary Resistance (TSR) After Interruption of Imatinib: Updated Results of the Prospective French Sarcoma Group Randomized Phase III Trial on.
Gemcitabine With or Without Cisplatin in Patients with Advanced or Metastatic Biliary Tract Cancer (ABC): Results of a Multicentre, Randomized Phase III.
CB-1 Background of Pancreatic Cancer & NCIC CTG PA.3 Study Design Malcolm Moore, MD Professor of Medicine and Pharmacology Princess Margaret Hospital Chair,
Impact of Bevacizumab (Bev) on Efficacy of Second-Line Chemotherapy (CT) for Triple- Negative Breast Cancer: Analysis of RIBBON-2 Brufsky A et al. Proc.
1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.
Moskowitz CH et al. Proc ASH 2014;Abstract 673.
A Phase III, Open-Label, Randomized, Multicenter Study of Eribulin Mesylate versus Capecitabine in Patients with Locally Advanced or Metastatic Breast.
PHASE II RANDOMIZED STUDY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 – POSITIVE.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.
Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.
Pazopanib in Advanced Ovarian Cancer: A new galloping horse. Dr. Raafat Ragaie, MD,FRCR.
Single-agent nab-Paclitaxel Given Weekly (3/4) as First-line Therapy for Metastatic Breast Cancer (An International Oncology Network Study, #I )
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian.
Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)
Slamon D et al. SABCS 2009;Abstract 62.
Alessandra Gennari, MD PhD
Azienda Ospedaliero Universitaria Policlinico Modena
Chicago 2008: Post - ASCO Analysis: Metastatic Breast Cancer
Blackwell KL et al. SABCS 2009;Abstract 61
ASCO 2002 Advances in the Adjuvant Chemotherapy of Breast Cancer
DR VANDERPUYE CONSULTANT RADIATION AND CLINICAL ONCOLOGIST GHANA
Vahdat L et al. Proc SABCS 2012;Abstract P
What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard
Swain SM et al. Proc SABCS 2012;Abstract P
Barrios C et al. SABCS 2009;Abstract 46.
Krop I et al. SABCS 2009;Abstract 5090.
Baselga J et al. SABCS 2009;Abstract 45.
Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.
Presentation transcript:

Use of Chemotherapeutic and Biologic Agents in Metastatic Breast Cancer Breast Cancer Update Medical Oncology Educational Forum May 21, 2005 Kathy D Miller MD Assistant Professor of Medicine Department of Hematology/Oncology Indiana University School of Medicine Indianapolis, Indiana

Sequential single-agent chemotherapy is more appropriate than the use of combination chemotherapy in most patients with metastatic disease. Bevacizumab, combined with paclitaxel or capecitabine is generally the preferred first-line chemotherapy for patients with metastatic disease. Agree, disagree or in between?

Trial Designs A + B vs C A + B vs A A + B vs A  B

AB vs A Doc. + Capecitabine (TX) vs Doc. (T) Randomization (3-weekly cycles) Capecitabine 1,250 mg/m 2 twice daily, days 1–14 Docetaxel 75 mg/m 2, day 1 Docetaxel 100 mg/m 2, day 1 Patients responding or with stable disease after 6 weeks of treatment continued until disease progression or unacceptable toxicity Crossover  20% Source: O’Shaughnessy J et al. J Clin Oncol 2002;20(12): Reproduced with permission from the American Society of Clinical Oncology.

Overall Survival Doc. + Capecitabine (TX) vs Doc. (T) Time (months) TX T Median (CI) 14.5 (12.3–16.1) 11.5 (9.8–12.7) Hazard ratio = (0.634–0.947) Log-rank p= ORR: 42% vs 30%; p=0.006 Source: O’Shaughnessy J et al. J Clin Oncol 2002;20(12): Reproduced with permission from the American Society of Clinical Oncology.

Treat until documented PD All sites of disease assessed every 8 weeks Paclitaxel 175 mg/m 2 (3 hr) Gemcitabine 1250 mg/m 2 Paclitaxel 175 mg/m 2 (3 hr) GT (21-day cycle) T (21-day cycle) Day 1: Gemcitabine 1250 mg/m 2 Day 8: RANDOMIZERANDOMIZE AB vs A Paclitaxel + Gem (GT) vs Paclitaxel (T) Prior adjuvant anthracycline required Crossover  14% Source: Albain K et al. Presentation. ASCO 2004.

0.78 (0.63, 0.96) Hazard ratio p=0.018 Log rank 18.5 mos mos. Interim Overall Survival Paclitaxel + Gem (GT) vs Paclitaxel (T) ORR: 40.8% vs 22.1% p< With permission from Albain K et al. Presentation. ASCO 2004.

RRTTPOS Heideman=== Norris=== Berruti=== Bishop=== French Epi/FECC== Ejlertsen=C= Nabholtz=SS SjostromSS= BonneterreSS O’ShaughnessyCCC AlbainCCCC AB vs A or C Docetaxel Capecitabine Gemcitabine

N = 303 Epi  MMCCEF  MMC/Vbn RR% DOR(mo) (p=.07) OS(mo)1618 (p=.62) Treatment related toxicity and QOL assessment favored sequential single agent therapy AB CD vs A C Sequential Combos vs Sequential Monos Source: Joensuu et al. J Clin Oncol 1998;16(12):

A60 mg/m 2 T175 mg/m 2 over 24 hours AT50 mg/m 2 3 hours 150 mg/m 2 over 24 hrs A(n=245)A(n=128) T(n=242)T(n=129) AT(n=244) AB vs A B vs B A E1193: Combination vs Sequential Source: Sledge G et al. J Clin Oncol 2003;21:

RR(%) TTF (mo.) OS (mo.) A T AT 47* 8.2* 22.4 *p A=.017 A=.002 T=.006 T=.057 QOL using FACT-B — no significant difference. Cross-over Results AT TA AB vs A B vs B A E1193: Combination vs Sequential Source: Sledge G et al. J Clin Oncol 2003;21:

RRTTPOS Baker=== SmalleyCC= ChlebowskiCC= Joensuu=== SledgeCC= AB vs A B

Goals of Therapy in MBC Individual Goals Extend survival Improve or maintain quality of life Clinical Trial Outcomes Response rate Response duration TTP TTF Overall survival Quality of life

Chemotherapy for MBC Sequential single agents preferred for most patients –Variety of options – no single ‘gold standard’ –Limits toxicity –Supported by clinical trial data Combinations appropriate for rapidly progressive symptomatic disease –Reduction in symptoms outweighs potential toxicity –May not be candidate for subsequent therapy if continued progression

E Rationale Tumor growth is dependent on angiogenesis Bevacizumab is a humanized monoclonal antibody directed against VEGF Recognizes all VEGF-A isoforms Active in patients with refractory MBC 9% response rate as monotherapy Increases ORR but not PFS in combination with capecitabine Greater activity expected in less heavily pre-treated patients Source: Miller KD et al. Presentation. ASCO 2005.

Stratify: DFI 24 mos. 3 metastatic sites Adjuvant chemotherapy yes vs no ER+ vs ER- vs ER unknown RANDOMIZERANDOMIZE Paclitaxel + Bevacizumab Paclitaxel E Study Design Source: Miller KD et al. Presentation. ASCO 2005.

E Key Eligibility Criteria Locally recurrent or metastatic breast cancer –HER2+ only if prior treatment with trastuzumab or contraindication No prior chemo regimens for MBC –Adjuvant taxane allowed if DFI > 12 months ECOG PS 0 or 1 No CNS mets (head CT or MR required) No significant proteinuria (> 500 mg/24 hr) No therapeutic anticoagulation Source: Miller KD et al. Presentation. ASCO 2005.

E Statistical Design Primary endpoint: Progression-Free Survival –85% power for a 33% improvement 6 vs 8 months –One-sided type I error  2.5% –Requires 650 eligible patients Final analysis after 546 PFS events –Interim analyses after 270 and 425 events –Asymmetric boundaries to stop early either for demonstrated benefit or for lack of benefit Source: Miller KD et al. Presentation. ASCO 2005.

E Current Analysis Study activated Dec 21, 2001 Closed March 24, 2004 –715 eligible patients First planned interim analysis Data cut-off February 9, events –Progression – 291 –Death without documented progression - 64 Source: Miller KD et al. Presentation. ASCO 2005.

E Patient Characteristics Paclitaxel (n=350) Pac. + Bev. (n=365) Treated Median age55 (27-85)56 (29-84) DFI < 24 months41% > 3 sites29%28% Adjuvant chemo.64%65% ER+63%64% Source: Miller KD et al. Presentation. ASCO 2005.

Measurable Disease All pat All patients ts Measurable Disease 0 E Response % 16.4% 28.2% 14.2% p< Overall Response Rate Paclitaxel Pac + Bev Source: Miller KD et al. Presentation. ASCO 2005.

E Progression Free Survival HR = ( ) Log Rank Test p<0.001 Months PFS Proportion Pac. + Bev months Paclitaxel 6.11 months Source: Miller KD et al. Presentation. ASCO 2005.

E Overall Survival Months OS Proportion Pac. + Bev. Paclitaxel HR = ( ) Log Rank Test p=0.01 Source: Miller KD et al. Presentation. ASCO 2005.

E Bevacizumab Toxicity NCI-CTC Grade 3 and 4 Paclitaxel (n=330) Pac. + Bev. (n=342) % Grade 3Grade 4Grade 3Grade 4 HTN* Thromboembolic Bleeding Proteinuria** NCI-CTC v3.0, worst per patient *p<0.0001; **p= Source: Miller KD et al. Presentation. ASCO 2005.

E Other Toxicities NCI-CTC Grade 3 and 4 NCI-CTC v3.0, worst per patient *p=0.01 Paclitaxel (n=330) Pac. + Bev. (n=342) % Grade 3Grade 4Grade 3Grade 4 Neuropathy* Fatigue Neutropenia  LVEF Source: Miller KD et al. Presentation. ASCO 2005.

Conclusions and Future Directions Addition of bevacizumab to paclitaxel –Significantly prolongs progression free survival –Increases objective response rate –Longer follow-up required to assess impact on OS Further studies should –Explore the role of Bevacizumab in the adjuvant setting –Develop methods to identify patients who are most likely to benefit from VEGF-targeted therapies Source: Miller KD et al. Presentation. ASCO 2005.

E2104 Adjuvant Pilot Trial REGISTERREGISTER Doxorubicin 60 mg/m 2 plus Cyclophosphamide 600 mg/m 2 Bevacizumab 10 mg/kg every 14 days x 4 Arm A: ddBAC >BT >B Arm B: ddAC >BT >B Doxorubicin 60 mg/m 2 plus Cyclophosphamide 600 mg/m 2 every 14 days x 4 Paclitaxel 175 mg/m 2 Bevacizumab 10 mg/kg every 14 days x 4 Bevacizumab 10 mg/kg every 14 days x 18 Bevacizumab 10 mg/kg every 14 days x 22 Hormone therapy and radiation per standard care Source: Miller KD et al. Presentation. ASCO 2005.

For most patients, weekly paclitaxel or capecitabine in combination with bevacizumab provide the most effective first-line therapy. Agree Agree, disagree or in between?

Bevacizumab Increased ORR, DFS and OS in combination with weekly paclitaxel –E2100 excluded patients progressing within 12 months of adjuvant taxanes Recent prior taxane –Safety and response data with capecitabine, vinorelbine in MBC

Capecitabine + Bevacizumab Cap (n=230) Cap + Bev (n=232) ORR (Inv)19.1%30.2% (p=0.006) ORR (IRF)9.1%19.8% (p=0.001) Source: Miller KD et al. J Clin Oncol 2005;23(4):792-9.

Vinorelbine + Bevacizumab Source: Burstein H et al. Poster 446. San Antonio Breast Cancer Symposium 2002.

XCaliBr Capecitabine 1000 mg/m 2 D Bevacizumab 15 mg/kg D1 Vinorelbine + Bevacizumab Paclitaxel + Bevacizumab Investigator/patient choice Newly diagnosed MBC N~92